AACR 2022 | KEYNOTE-B84: pepinemab + pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma

Terrence L. Fisher, PhD, Vaccinex Inc., Rochester, NY, discusses the Phase I/II KEYNOTE-B84 trial (NCT04815720) of pepinemab plus pembrolizumab as a first-line treatment in patients with metastatic or recurrent head and neck squamous cell carcinoma. Data from the safety run-in stage was presented at AACR 2022, including the recommended Phase II dosage. This interview took place at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, LA.